Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Purchases $86,200.00 in Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 4,000 shares of the firm’s stock in a transaction dated Thursday, May 15th. The stock was purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the purchase, the chief executive officer now directly owns 4,005 shares of the company’s stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tonix Pharmaceuticals Trading Up 21.2%

Tonix Pharmaceuticals stock opened at $28.00 on Friday. The firm’s 50-day moving average is $18.93 and its 200-day moving average is $20.92. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals Holding Corp. has a 1 year low of $6.76 and a 1 year high of $659.20. The company has a market cap of $205.10 million, a P/E ratio of -0.01 and a beta of 1.63.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.43 million for the quarter, compared to analysts’ expectations of $2.55 million. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TNXP shares. StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They set a “sell” rating on the stock. Noble Financial reiterated an “outperform” rating and set a $70.00 price objective on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th.

Institutional Trading of Tonix Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TNXP. Commonwealth Equity Services LLC bought a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth approximately $40,000. Two Sigma Investments LP bought a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth approximately $66,000. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals in the fourth quarter worth approximately $72,000. Northern Trust Corp purchased a new position in shares of Tonix Pharmaceuticals in the fourth quarter worth approximately $162,000. Finally, IFP Advisors Inc purchased a new position in shares of Tonix Pharmaceuticals in the first quarter worth approximately $179,000. 82.26% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.